NYSE
$4.57▲ 0.33%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.59BShares out 3.500M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 8.21After-hours26.08.22 05:494Ownership#●●●
Nuvation Bio Inc.
Insider Gary Hattersley of Nuvation Bio Inc. filed a Form 4 report on August 21, 2026, regarding changes in beneficial ownership of securities effective August 19, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$4.57+0.33%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.19After-hours26.08.20 05:30144Ownership
Nuvation Bio Inc.
Gary Hattersley, an insider at Nuvation Bio Inc., filed Form 144 with the SEC on August 19, 2026, to announce the proposed sale of company shares. This filing formalizes the executive's plan to dispose of his holdings, which will result in an increase in the supply of shares in the market.…more
$4.57+0.33%vs prev closeView filingShare - 8.6Pre-market26.08.06 20:308-KKey event
Nuvation Bio Inc.
누베이션 바이오(Nuvation Bio)는 2026년 2분기 3,170만 달러의 총 매출을 기록했으며, 이 중 주력 제품인 IBTROZI의 순매출은 2,320만 달러를 달성했습니다. 회사는 6월 30일 기준 6억 6,100만 달러의 현금 및 현금성 자산을 보유하고 있으며, 사푸시데닙(safusidenib)의 임상 프로그램 확장과 함께 IDH1 변이 신경교종 치료제 개발을 가속화하고 있습니다.…more
$4.57+0.33%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.17Regular26.09.18 01:46Bullish#●●●#●●●
Nuvation Bio Shares Jump 6% Following FDA Approval for IBTROZI
Nuvation Bio's oncology drug IBTROZI received FDA approval for a label update confirming extended clinical benefits, four months ahead of schedule. The positive regulatory milestone highlights the drug's long-term efficacy and safety, driving a significant rise in the company's stock price.…more
$4.57+0.33%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.17Pre-market26.09.17 20:32
●●●●●●●● ●●●●● ●●●●●●
Nuvation Bio announced FDA approval of its supplemental New Drug Application for IBTROZI, a treatment for ROS1-positive non-small cell lung cancer. The update incorporates long-term clinical data confirming the drug's sustained efficacy and safety profile.…more
$4.57+0.33%vs prev closeShareBenzinga - 9.15Pre-market26.09.15 21:06
●●●●●●●● ●●●●● ●●●●●●
Nuvation Bio announced new subgroup analyses from its pivotal TRUST-I and TRUST-II studies, demonstrating consistent efficacy of IBTROZI in advanced ROS1+ NSCLC patients. The data confirms the drug's effectiveness regardless of prior chemotherapy or specific fusion partners.…more
$4.57+0.33%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report